Virus inactivation in blood

AIDS

Volumn 10, Issue 11, 1996, Pages 1183-1190

  Ben Hur, Ehud ^a   Horowitz, Bernard ^a  

^a Melville Biologics Inc   (United States)

Author keywords

Blood transfusion; Photosensitization; Transmission of viruses; Virus inactivation

Indexed keywords

BLOOD SUBSTITUTE; THROMBOCYTE CONCENTRATE;

BLOOD TRANSFUSION; ERYTHROCYTE CONCENTRATE; PHOTOSENSITIZATION; PRIORITY JOURNAL; REVIEW; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0029790712     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199609000-00002     Document Type: Review

References (84)

1. Selik RM, Ward JW, Buehler JW: Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion 1993, 33:890-893.
2. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA: Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991, 31:4-11.
3. Petersen LR, Satten GA, Dodd RY, et al.: Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994, 34:283-289.
4. Dodd RY: The risk of transfusion-transmitted infection. N Engl J Med 1992, 327:419-421.
5. Donahue JG, Munoz A, Ness PM, et al.: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992, 327:369-373.
6. Sloand EM, Pitt E, Klein HG: Safety of the blood supply. JAMA 1995, 274:1368-1373.
7. Goedert JJ, Kessler CM, Aledort LM, et al.: A prospective study of human immunodeficiency infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989, 321:1141-1148.
8. Brettler DB, Alter HJ, Dienstag JL, Frosberg AD, Levine PH: The prevalence of antibody to hepatitis C in a cohort of hemophilic patients [letter]. Blood 1990, 76:254.
9. Blemchet VS, Vorstman E, Shore A, et al.: Hepatitis C infection in children with hemophilia A and B. Blood 1991, 78:285-289.
10. Troisi CL, Hollinger FB, Hoots WK, et al.: A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993, 81:412-418.
11. Oliphant JW, Hollaender A: Homologous serum jaundice: experimental inactivation of etiologic agent in serum by ultraviolet irradiation. Public Health Rep 1946, 61:598-600.
12. Murray R, Oliphant JW, Tripp JT, Hampi B, Ratner F, Deitenbach WCL: Effect of ultraviolet irradiation on the infectivity of icterogenic plasma. J Am Med Assoc 1955, 157:8-14.
13. Hilfenhaus J, Herrman A, Mauler R, Prince AM: Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization. Vox Sang 1986, 50:208-211.
14. Hilfenhaus J, Weidmann E: Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates. Arzneimittelforsch 1986, 36:621-625.
15. Horowitz B, Wiebe ME, Lippin A, Vandersand J, Stryker MH: Inactivation of viruses in labile blood derivatives. II. Physical methods. Transfusion 1985, 25:523-527.
16. Hollinger B, Dolana G, Thomas W, Gyorkey F: Reduction in risk of hepatitis transmission by heat treatment of a factor VIII concentrate. J Infect Dis 1984, 150:250-262.
17. Levy JA, Mitra G, Mozen MM: Recovery and inactivation of infectious retroviruses added to factor VIII concentrates [letter]. Lancet 1984, ii:722-723.
18. Winkelman L, Owen NE, Evans DR, et al.: Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989, 57:97-103.
19. Mannucci PM: Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993, 64:197-203.
20. Horowitz B, Wiebe ME, Lippin A, Stryker MH: Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985, 25:516-522.
21. Horowitz B, Prince AM, Hamman J, Watklevicz C: Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinol 1994, 5 (suppl):S21-S28.
22. Prince AM, Horowitz B, Baker L, et al.: Failure of a human immunodeficiency virus (HIV) immune globulin to protect against experimental challenge with HIV. Proc Natl Acad Sci USA 1988, 85:6944-6948.
23. Horowitz B: Inactivation of viruses found with plasma proteins. In Biotechnology of Blood. Edited by Goldstein J. Stoneham: Butterworth-Heinemann; 1991:417-430.
24. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW: Solvent/detergent-treated plasma: a virus inactivated substitute for fresh frozen plasma. Blood 1992, 79:826-831.
25. Lemon SM, Murphy PC, Smith A, Zou J, Hamman A: Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J Med Virol 1994, 43:44-49.
26. Piquet Y, Janvier G, Selosse P, et al.: Virus inactivation of fresh frozen plasma by a solvent-detergent procedure: biological results. Vox Sang 1992, 63:251-256.
27. Hellstern P, Sachse H, Schwinn H, Oberfrank K: Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992, 63:178-185.
28. Solheim BG, Svennevig JL, Mohr B, et al.: The use of Octasplas in patients undergoing open heart surgery. In DIS: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Edited by Muller-Berghanns G, et al. Amsterdam: Elsevier Science Publishers; 1993:253-262.
29. Moake J, Chintagumpala M, Turner J, et al.: Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994, 84:490-497.
30. Pehta JC: Clinical studies with solvent detergent-treated plasma. Transfusion Med Audio Updates 1994.
31. Piszkiewicz D, Sun CS, Tondreau SC: Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemophil M). Thromb Res 1989, 55:627-634.
32. Hrinda ME, Feldman F, Schreiber AB: Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol 1990, 27 (suppl 2):S19-S24.
33. Hamamoto Y, Harada S, Kobayashi S, et al.: A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sang 1989, 56:230-236.
34. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T: Nanofiltration, a new specific virus elimination method applied to high purity factor IX and factor XI concentrates. Vox Sang 1994, 67:132-138.
35. Horowitz B, Zou J, Hamman J, et al.: Elimination of small, heat-and solvent/detergent (S/D)-resistant viruses in factor VIII concentrate and fibrin sealant [letter]. Thromb Haemost 1995, 73:1460.
36. Rauth AM: The physical state of viral nucleic acid and the sensitivity of viruses to ultraviolet light. Biophys J 1965, 5:257-273.
37. Chin S, Williams B, Gottlieb P, et al.: Virucidal UVC treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Blood 1995, 86:4331-4336.
38. Marx G, Mou X, Freed R, Ben-Hur E, Yang C, Horowitz B: Protecting fibrinogen with rutin during UVC irradiation for viral inactivation. Photochem Photobiol 1996, 63:541-546.
39. Highsmith FA, Caple M, Walthall B, Shanbrom E, Drohan WN: Viral inactivation of vesicular stomatitis virus in normal human serum by crosslinked polyvinylpyrrolidone. J Infect Dis 1993, 167:1027-1033.
40. Highsmith FA, Xue H, Caple M, Walthall B, Drohan WN, Shanbrom E: Inactivation of lipid-enveloped and non-lipid-enveloped model viruses in normal human plasma by crosslinked starch-iodine. Transfusion 1994, 34:322-327.
41. Wallis C, Melnick JL: Photodynamic inactivation of animal viruses: a review. Photochem Photobiol 1965, 4:159-170.
42. Specht K: The role of DNA damage in PM2 viral inactivation by methylene blue photosensitization. Photochem Photobiol 1994, 59:506-514.
43. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H: Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991, 60:207-213.
44. Wieding JU, Neumeyer H: Erste erfahrungen mit methylenblauvirus inaktiviertem fresh-frozen-plasma: ergebuisse einer clinischen und an einer in vitro-studie. Infusiontherapie 1992, 19:84-90.
45. Mohr H, Knuver-Hopf J, Lambrecht B, Scheidecker H, Schmitt H: No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol 1992, 65:224-228.
46. Zeiler T, Riess H, Wittmann G, et al.: The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994, 34:685-689.
47. Wagner SJ, Cifone MA, Murli H, Dodd RY, Myhr B: Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion 1995, 35:407-413.
48. Miolo G, Tomanin R, DeRossi A, Dall'Acqua F, Zacchello F, Scarpa M: Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus. J Photochem Photobiol B 1994, 26:241-247.
49. Ben-Hur E, Song PS: Photochemistry and photobiology of furocoumarins (psoralens). Adv Radiat Biol 1984, 11:131-171.
50. Margolis-Nunno H, Robinson R, Ben-Hur E, Horowitz B: Quencher enhanced specificity of psoralens photosensitized viral inactivation in platelet concentrates. Transfusion 1994, 34:802-810.
51. Wollowitz S, Fang Y, Jiatao P, et al.: Novel psoralens with enhanced UVA dependent inactivation of human immunodeficiency virus and reduced mutagenicity in the absence of UV light. Blood 1993, 82 (suppl 1):402A.
52. Margolis-Nunno H, Robinson R, Ben-Hur E, Chin S, Orme T, Horowitz B: Elimination of potential mutagenicity in platelet concentrates that are virally inactivated with psoralens and ultraviolet A light. Transfusion 1995, 35:855-862.
53. Margolis-Nunno H, Robinson R, Horowitz B, Geacintov NE, Ben-Hur E: Psoralen-mediated virus photoinactivation in platelet concentrates: enhanced specificity of virus kill in the absence of shorter UVA wavelengths. Photochem Photobiol 1995, 62:917-922.
54. Gottlieb P, Margolis-Nunno H, Robinson R, et al.: Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a psoralen and ultraviolet A light. Photochem Photobiol 1996, 63:562-565.
55. Lin L, Londe H, Janda JM, Hanson CV, Corash L: Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood 1994, 83:2698-2706.
56. Benade LE, Shumaker J, Xu Y, Shen X, Dood RY: Inactivation of free and cell-associated human immunodeficiency virus in platelet suspensions by aminomethylpsoralen and ultraviolet light. Transfusion 1994, 34:680-684.
57. Piet B, Legrand-Poels S, Sappey C, Piette J: NF-κB transcription factor and human immunodeficiency virus type 1 (HIV-1) activation by methylene blue photosensitization. Eur J Biochem 1995, 228:447-455.
58. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L: Differential sensitivities of viruses in red cell suspension to methylene blue photosensitization. Transfusion 1994, 34:521-526.
59. Wagner SJ, Storry JR, Mallory DA, Stromber RR, Benade LE, Friedman LI: Red cell alterations associated with virucidal methylene blue phototreatment. Transfusion 1993, 33:30-36.
60. North J, Coombs R, Levy J: Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative. J Acquir Immune Defic Syndr 1994, 7:891-898.
61. Meruelo D, Lavie G, Lavie D: Therapeutic agents with dramatic antiretroviral activity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 1988, 85:5230-5234.
62. Lavie G, Mazur Y, Lavie D, et al.: Hypericin as an inactivator of infectious virus in blood products. Transfusion 1993, 35:392-400.
63. Ben-Hur E, Malik Z, Dubbelman TMAR, Margaron P, Ali H, van Lier JE: Phthalocyanine-induced photohemolysis: structure-activity relationship and the effect of fluoride. Photochem Photobiol 1993, 58:351-355.
64. Rywkin S, Lenny L, Goldstein J, Geacintov NE, Margolis-Nunno H, Horowitz B: Importance of type I and type II mechanisms in the photodynamic inactivation of viruses in blood with aluminum phthalocyanine derivatives. Photochem Photobiol 1992, 56:463-469.
65. Rywkin S, Ben-Hur E, Malik Z, et al.: New phthalocyanines for photodynamic viral inactivation in red blood cell concentrates. Photochem Photobiol 1994, 60:165-170.
66. Margolis-Nunno H, Ben-Hur E, Gottlieb P, Robinson R, Oetjen J, Horowitz B: Inactivation of multiple forms of human immunodeficiency virus in red cell concentrates by phthalocyanine photosensitization Transfusion 1996, 36: (in press).
67. Gottlieb P, Shen LG, Chimezie E, et al.: Inactivation of Trypanosoma cruzi trypomastigote forms in blood components by photodynamic treatment with phthalocyanines. Photochem Photobiol 1995, 62:869-874.
68. Lustigman S, Ben-Hur E: Photosensitized inactivation of Plasmodium falciparum in human erythrocytes by phthalocyanines. Transfusion 1996, 36:562-565.
69. Ben-Hur E, Rywkin S, Rosenthal I, Geacintov NE, Horowitz B: Virus inactivation in red cell concentrates by photosensitization with phthalocyanines: protection of red cells but not of vesicular stomatitis virus with a water-soluble analog of vitamin E. Transfusion 1995, 35:401-406.
70. Rywkin S, Ben-Hur E, Reid ME, Oyen R, Ralph H, Horowitz B: Selective protection against IgG binding to red cells treated with phthalocyanines and red light for virus inactivation. Transfusion 1995, 35:414-420.
71. Ben-Hur E, Zuk MM, Chin S, Banerjee D, Kenney ME, Horowitz B: Biodistribution and virus inactivation efficacy of the silicon phthalocyanine Pc 4 in red blood cell concentrates as a function of delivery vehicle. Photochem Photobiol 1995, 62:575-579.
72. Ben-Hur E, Geacintov NE, Studamire B, Kenney ME, Horowitz B: The effect of irradiance on virus sterilization and photodynamic damage in red blood cells sensitized by phthalocyanines. Photochem Photobiol 1995, 61:190-195.
73. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: implication for therapy. Science 1993, 262:1011-1018.
74. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993, 57:183-289.
75. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
76. Bisaccia E, Berger C, Klainer A: Extracorporeal photopheresis in the acquired immunodeficiency syndrome (AIDS)-related complex - a pilot study. Ann Intern Med 1990, 113:270-275.
77. Bisaccia E, Berger C, Armus S, Cahill C, Klainer A: Viral-specific immunization in ARC by photopheresis. Ann NY Acad Sci 1991, 636:321-331.
78. Wolinsky SM, Korber BTM, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272:537-542.
79. Gonzalez J, Berger C, Cottrill CM, et al.: Cytolytic response to HIV in patients with HIV disease treated with extracorporeal photochemotherapy: preliminary study. Photochem Photobiol 1996, 63:558-561.
80. Chowdhary RK, Ratkay LG, Jeyndorff HC, et al.: The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice. Clin Immunol Immunopathol 1994, 72:255-263.
81. Tremper KK, Friedman AE, Levine EM, et al.: The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid. Fluosol-DA. N Engl J Med 1982, 307:277-283.
82. Spence RK, McCoy S, Costabile J, et al.: Fluosol DA-20 in the treatment of severe anemia: randomized controlled study of 46 patients. Crit Care Med 1990, 18:1227-1230.
83. 2 carrier. Ann Surg 1990, 211:394-398.
84. Vlahakes GJ, Lee R, Jacobs EE, et al.: Hemodynamic effects and oxygen transport properties of a new blood substitute in a model of massive blood replacement. J Thorac Cardiovasc Surg 1990, 100:379-388.